High-levelERBB2gene amplification is associated with a particularly short time-to-metastasis, but results in a high rate of complete response once trastuzumab-based therapy is offered in the metastatic setting

In situ detection of HER2:HER2 and HER2:HER3 protein–protein interactions demonstrates prognostic significance in early breast cancer

(2011) Melanie Spears et al.   BREAST CANCER RESEARCH AND TREATMENT

Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers

(2011) R. Ghosh et al.   CANCER RESEARCH

Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab

(2010) Allan Lipton et al.   CANCER

Quantitation of HER2 Expression or HER2:HER2 Dimers and Differential Survival in a Cohort of Metastatic Breast Cancer Patients Carefully Selected for Trastuzumab Treatment Primarily by FISH

(2009) Christine Desmedt et al.   DIAGNOSTIC MOLECULAR PATHOLOGY

Effect of High Copy Number of HER2 Associated With Polysomy 17 on HER2 Protein Expression in Invasive Breast Carcinoma

(2009) Sejal S. Shah et al.   DIAGNOSTIC MOLECULAR PATHOLOGY

Disease-Free Survival According to Degree ofHER2Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial

(2009) Mitch Dowsett et al.   JOURNAL OF CLINICAL ONCOLOGY

Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations

(2009) Guido Sauter et al.   JOURNAL OF CLINICAL ONCOLOGY

Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response

(2009) Monica M Reinholz et al.   LANCET ONCOLOGY

Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer

(2008) Giuseppe Gullo et al.   INVESTIGATIONAL NEW DRUGS